Quisinostat (dihydrochloride)

Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally active, potent pan-HDAC inhibitor with IC50s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity. Quisinostat dihydrochloride can induce autophagy in neuroblastoma cells[1][2].

Product Specifications

CAS Number

[875320-31-3]

Product Name Alternative

JNJ-26481585 (dihydrochloride)

UNSPSC

12352005

Target

Autophagy; HDAC

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/quisinostat-dihydrochloride.html

Purity

99.05

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 70°C)

Smiles

[H]Cl.O=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO.[H]Cl

Molecular Formula

C21H28Cl2N6O2

Molecular Weight

467.39

References & Citations

[1]Vamsi Krishna Kommalapati, et al. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Mol Cell Biochem. 2020 May;468 (1-2) :21-34.|[2]Arts J, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15 (22) :6841-51.